Industry Overview

Melanoma cancer market was valued at $10.5 billion in 2025 and is projected to reach $27.3 billion by 2035, growing at a CAGR of 10.1% during the forecast Period (2026-2035). The market is growing due to increasing melanoma incidence from UV exposure and aging populations, advancements in targeted and immunotherapy treatments, and a focus on early detection through better diagnostics and awareness. These factors drive market expansion through investment in R&D, a robust pipeline of new drugs, and the increasing adoption of personalized and combination therapies.

Market Dynamics

Rising Global Incidence and Early Detection of Melanoma

A major driver of the global melanoma cancer market is the steady rise in melanoma incidence worldwide, fueled by increased UV exposure, genetic predispositions, and changing lifestyle patterns. Public awareness campaigns and dermatology outreach programs have enhanced recognition of suspicious skin lesions, resulting in more individuals seeking medical evaluation earlier. The expansion of routine skin checks, tele-dermatology platforms, and dermoscopy in clinical settings has significantly improved early detection rates. Early diagnosis typically leads to more successful treatment outcomes and increases the number of patients eligible for both surgical and adjuvant therapies. As a result, the growing global burden of melanoma continues to expand the overall demand for diagnostic tests, imaging procedures, and therapeutic interventions.

Technological Advancements in Immunotherapy and Targeted Treatments

The rapid evolution of melanoma treatment primarily through immunotherapies such as PD-1 and CTLA-4 inhibitors remains one of the strongest drivers of market growth. These therapies have dramatically improved survival outcomes for advanced-stage patients, leading to widespread adoption globally. The introduction of combination immunotherapies, personalized cancer vaccines, and cell-based immunotherapies is further accelerating market expansion. In parallel, targeted therapies for BRAF- and MEK-positive tumors continue to play a critical role in precision oncology, enabling more tailored treatment approaches. Ongoing clinical trials, expanded regulatory approvals, and increasing physician preference for advanced therapeutic regimens are creating sustained demand for innovative melanoma drugs.

Expanding Healthcare Infrastructure and Access to Advanced Oncology Care

Improving healthcare infrastructure across emerging markets such as the Asia-Pacific and Latin America is also driving the melanoma market growth. Governments and healthcare providers are investing heavily in cancer care facilities, early screening programs, and modern diagnostic technologies, making melanoma services more accessible to wider populations. Insurance coverage and reimbursement policies for oncology treatments are improving, enabling greater adoption of high-cost immunotherapies and targeted drugs. Additionally, pharmaceutical companies are expanding their presence in these regions through partnerships, market expansion initiatives, and clinical trial networks. As awareness increases and access to advanced care improves, patient uptake of both diagnostic procedures and novel therapies continues to rise, reinforcing the overall growth trajectory of the global melanoma cancer market.

Market Segmentation

• Based on the diagnosis, the market is segmented into biopsy, computed tomography (CT) scan, magnetic resonance imaging (MRI), and others (PET).
• Based on the therapy, the market is segmented into immunotherapy, targeted therapy, chemotherapy, and radiation therapy.

Immunotherapy Segment to Grow at a Considerable Market Share

Among all the diagnosis and therapy segments, Immunotherapy stands out as the largest and most dominant segment driving the Global Melanoma Cancer Market. Over the past decade, immunotherapy, particularly checkpoint inhibitors such as anti–PD-1 (nivolumab, pembrolizumab) and anti-CTLA-4 (ipilimumab), has revolutionized melanoma treatment by significantly improving survival, response rates, and long-term disease control compared with traditional chemotherapy and radiation therapy. Its dominance is further supported by expanding approvals in adjuvant, neoadjuvant, and advanced melanoma settings, making it the standard of care globally. Additionally, ongoing clinical trials, favorable reimbursement policies, and the rapid integration of combination immunotherapy regimens continue to strengthen its market share. As a result, immunotherapy not only surpasses chemotherapy, radiation therapy, and targeted therapy in adoption but also contributes the highest revenue to the overall melanoma cancer market globally.

Biopsy: A Key Segment in Market Growth

Among all diagnostic segments in the global melanoma cancer market, biopsy, CT Scan, MRI, and Others (PET)biopsy stands out as the key segment driving market growth, primarily due to its indispensable role in confirming melanoma and guiding subsequent treatment decisions. Biopsy remains the gold standard for melanoma diagnosis because no imaging modality alone can definitively detect malignancy or determine tumor characteristics with the accuracy required for clinical decision-making. As melanoma incidence continues to rise globally, the number of biopsies performed annually has increased substantially, driven by heightened public awareness, improved dermatology screening programs, and widespread use of dermoscopy that prompts early suspicious-lesion evaluation.

Advancements in biopsy techniques, such as punch biopsies, excisional biopsies, and shave biopsies, have further enhanced diagnostic accuracy while reducing procedural time and costs, making them more accessible across both developed and emerging healthcare systems. In addition, the integration of molecular and genetic profiling within biopsy samples has significantly expanded the clinical value of this segment, enabling precision treatment selection, particularly for targeted therapies such as BRAF and MEK inhibitors. Because biopsy directly influences disease staging, treatment planning, and long-term prognosis, its demand continues to grow in parallel with the expanding therapeutic landscape. As a result, biopsy remains the most essential and fastest-growing diagnostic category within the melanoma cancer market.

Regional Outlook

The global melanoma cancer market is further divided by geography, including North America (the US and Canada), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), and the Rest of the World (the Middle East & Africa, and Latin America).

North America  Region to Hold a Substantial Growth Rate

In North America, the US dominates the global melanoma cancer market with the largest share, driven by its high disease prevalence, advanced healthcare infrastructure, and strong adoption of cutting-edge oncology treatments. The US reports one of the highest melanoma incidence rates globally, which significantly expands the patient base requiring continuous diagnostic evaluation and advanced therapeutic interventions. The country also leads in the availability and utilization of innovative immunotherapies such as PD-1 and CTLA-4 inhibitors, along with targeted therapies like BRAF and MEK inhibitors, supported by a robust reimbursement framework that enables broad patient access to high-cost oncology drugs.

Furthermore, the US has a highly developed diagnostic landscapecomprising dermoscopy, digital imaging systems, high-precision biopsies, and molecular profiling drives early detection, improving treatment outcomes and expanding overall market value. Strong R&D investment, the presence of leading pharmaceutical giants such as Merck, Bristol-Myers Squibb, Pfizer, and Novartis, and active clinical trial pipelines reinforce the country’s leadership position. Additionally, widespread patient awareness campaigns conducted by organizations such as the American Academy of Dermatology further contribute to early screening and increased testing rates. As a result, the US continues to maintain the largest and most influential share of the global melanoma cancer market.

Market Players Outlook

The major companies operating in the global melanoma cancer market include Bristol-Myers Squibb Co., F. Hoffmann-La Roche AG, Merck & Co., Inc., Novartis AG, Pfizer Inc., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisitions to expand their businesses and develop innovative products to maintain their market positioning.

Recent Developments

• In February 2025, the FDA approved Amtagvi (lifileucel), the first cellular therapy for treating unresectable or metastatic melanoma in adults, particularly after other therapies have failed. Melanoma, a serious skin cancer often linked to UV exposure, poses a high risk of metastasis if not treated early. Treatment typically involves immunotherapy with PD-1 inhibitors and targeted BRAF therapies for mutations. Amtagvi, derived from a patient's own T cells, represents a significant advancement as it is the first FDA-approved tumor-derived T cell immunotherapy, aimed at patients with crucial unmet medical needs.
• In April 2025, Skin cancer patients in England will be fast-tracked into trials for a new cancer vaccine as part of the NHS's expanded programme. This needle-free vaccine boosts the immune system to recognize and attack cancer cells over two years. The NHS, in collaboration with Scancell, has registered seven hospital sites for the trial, with referrals expected to begin next month. This initiative is part of the Cancer Vaccine Launch Pad (CVLP), which has previously facilitated access to personalized bowel cancer vaccines for over 350 patients and is now also focusing on melanoma trials.

The Report Covers

• Market value data analysis for 2025 and forecast to 2035.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global melanoma cancer market. Based on the availability of data, information related to new products and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.